Results 11 to 20 of about 4,852 (207)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide [PDF]

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +3 more sources

Emtricitabine/Tenofovir Alafenamide Fumarate [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide [PDF]

EBioMedicine, 2016
Background: Initiation of antiretroviral therapy (ART) and subsequent virologic suppression reduces immune activation and systemic inflammation. Methods: We examined longitudinal changes in biomarkers of monocyte activation (sCD14, sCD163), and systemic (
Nicholas T. Funderburg, Grace A. McComsey, Manjusha Kulkarni, Tammy Bannerman, Jessica Mantini, Bernadette Thornton, Hui C. Liu, Yafeng Zhang, Qinghua Song, Liang Fang, Jason Dinoso, Andrew Cheng, Scott McCallister, Marshall W. Fordyce, Moupali Das   +14 more
doaj   +3 more sources

Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

CPT: Pharmacometrics & Systems Pharmacology, 2023
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma, Roeland E. Wasmann, Phumla Sinxadi, Simiso M. Sokhela, Nomathemba Chandiwana, Willem D. F. Venter, Lubbe Wiesner, Gary Maartens, Paolo Denti   +8 more
doaj   +3 more sources

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate

Pharmaceutical Fronts, 2023
(R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj   +2 more sources

Point-of-care semiquantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate [PDF]

Journal of Antimicrobial Chemotherapy, 2021
Abstract Objectives Objective measurement of antiretrovirals may aid clinical interventions for improving adherence to HIV prevention or treatment regimens. A point-of-care urine test could provide real-time information about recent adherence to regimens containing tenofovir disoproxil fumarate
Derin Sevenler, Xin Niu, Sandy Dossantos, Mehmet Toner, Tim R. Cressey, Rebecca D. Sandlin, Paul K. Drain   +6 more
openalex   +3 more sources

Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +3 more sources

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. [PDF]

Sci Rep
Shi F, Xia H, Weissman S, Li X, Yang X.
europepmc   +2 more sources

Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate [PDF]

Turk J Pharm Sci, 2021
Attaluri T, Seru G, Varanasi SNM.
europepmc   +2 more sources